PSA progression compared to radiographic or clinical progression in metastatic castration-resistant prostate cancer patients treated with enzalutamide.Shruti U. Gandhy, Ravi A. Madan, Amy Hankin et al.|Journal of Clinical Oncology|2020Cited by 7
1412P Immune changes after enzalutamide (Enza) is added to androgen-deprivation therapy (ADT) in first-line metastatic castration-resistant prostate cancer (mCRPC)Ravi A. Madan, James L. Gulley, Renee N. Donahue et al.|Annals of Oncology|2022Cited by 2
1614P PSA responses and PSMA scan changes after immunotherapy for biochemically recurrent prostate cancer (BCR) without androgen deprivation therapy (ADT)Ravi A. Madan, Fatima Karzai, Esther Mena Gonzalez et al.|Annals of Oncology|2024Cited by 2
Evaluating biomarkers in metastatic castration-resistant prostate cancer patients treated with enzalutamide: PSA, circulating tumor cell counts, AR-V7 status and radiographic progression.Shruti U. Gandhy, Ravi A. Madan, Fatima Karzai et al.|Journal of Clinical Oncology|2020Cited by 1